Published • loading... • Updated
Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
Summary by The Manila Times
1 Articles
1 Articles
Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
Milestone achievement advances potential first FDA-approved disease-modifying therapy for pterygium, a condition affecting just under one billion people globally, including 15...
·Manila, Philippines (the)
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
